AVANIR Pharmaceuticals (NASDAQ:AVNR)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

Results 1 - 20 of 38 : 1 2 Next »

Recs

0
Member Avatar rogue66 (29.78) Submitted: 2/8/2014 12:44:07 PM : Outperform Start Price: $3.58 AVNR Score: -6.46

just a guess

Recs

0
Member Avatar habibnor (50.88) Submitted: 10/7/2013 2:43:16 PM : Outperform Start Price: $4.55 AVNR Score: -34.42

Obamacare !

Recs

0
Member Avatar fatmoneyrz (94.34) Submitted: 9/16/2013 10:01:29 AM : Outperform Start Price: $4.38 AVNR Score: -29.79

$30 dollar price target by Piper Jaffray. Sell off overblown, some significant upside here after Delaware court ruling.

Recs

0
Member Avatar jmontgomery86 (68.87) Submitted: 6/13/2013 8:49:04 PM : Outperform Start Price: $4.45 AVNR Score: -35.44

$8 PT on Nuedexta growth and European acceptance.

Recs

0
Member Avatar WakeUpInvestor (44.10) Submitted: 6/5/2013 5:19:03 PM : Outperform Start Price: $3.85 AVNR Score: -25.21

Lead product will be marketed in Europe this year.

Recs

0
Member Avatar headyinvestor (83.83) Submitted: 4/11/2012 8:43:27 AM : Underperform Start Price: $3.14 AVNR Score: +24.89

This company is trading at 50x revenue! Really!?

Recs

0
Member Avatar 1stMartian (23.33) Submitted: 12/6/2011 1:25:08 PM : Underperform Start Price: $2.50 AVNR Score: +8.18

Declining sales, declining cash flow, horrible ROI.

Recs

0
Member Avatar ramirogon (< 20) Submitted: 5/3/2011 7:23:43 PM : Outperform Start Price: $4.18 AVNR Score: -54.17

avnr

Recs

0
Member Avatar dgoldmeier (21.34) Submitted: 2/9/2011 5:23:42 PM : Outperform Start Price: $4.02 AVNR Score: -55.11

If sales on Nuxedta go well this company can hit a homerun. Well worth the risk.

Recs

0
Member Avatar bw64588 (< 20) Submitted: 2/8/2011 6:20:12 AM : Outperform Start Price: $4.18 AVNR Score: -57.90

AVNR is going to surprise everyone. I look for it to start running in March when we hear the first reports of sales figures for Neudexta.

Recs

1
Member Avatar peter1568 (< 20) Submitted: 11/25/2010 12:28:41 PM : Outperform Start Price: $4.30 AVNR Score: -75.58

avnr is a takeover target for big business, has approved drug, little or no debt and enough money for its production and distribution, I believe that large company that already has spoken waiting for the Q4 11/30/2010 to offer for the shares, the next month I see some of these big companies could get started talking to avnr to buy next year

Recs

0
Member Avatar upordownimup (< 20) Submitted: 11/16/2010 3:21:12 PM : Outperform Start Price: $4.60 AVNR Score: -82.71

New drug approved in hostile climate for new drugs. I think Abreva works like magic. Love their discovery method.

Recs

0
Member Avatar BadCopNoDonuts (< 20) Submitted: 11/1/2010 11:52:45 AM : Underperform Start Price: $5.10 AVNR Score: +88.56

I just bought March Puts for cheap. Kind of a no-brainer.

Recs

6
Member Avatar BioInvestor217 (< 20) Submitted: 9/29/2010 12:08:15 AM : Outperform Start Price: $3.32 AVNR Score: -58.17

Solid fundamentals and very good drug pipeline. See below for more info on their drug AVP-923 which is due for FDA review October 30th 2010. Expect to see major run-up and positive news. Conserative target before news: $4.25-$4.50. Clinical tests and trials look good, overall very good outlook.

"AVANIR is developing AVP-923 for use in PBA (also known as involuntary emotional expression disorder (IEED) and emotional lability) and diabetic peripheral neuropathic pain."

Recs

0
Member Avatar ebitdat (< 20) Submitted: 9/16/2010 8:16:26 PM : Outperform Start Price: $2.72 AVNR Score: -36.92

Expect a run-up to approval date

Recs

0
Member Avatar venkybt (< 20) Submitted: 7/13/2010 2:24:37 PM : Outperform Start Price: $3.51 AVNR Score: -70.95

As a new drug in the market with good safety profile always clicks,,,,,

Recs

0
Member Avatar Cosmo21 (< 20) Submitted: 6/12/2010 7:03:08 PM : Outperform Start Price: $2.75 AVNR Score: -42.08

Approval coming soon. Potential 9 $ stock.

Recs

0
Member Avatar LonWa (< 20) Submitted: 5/29/2010 10:46:01 AM : Outperform Start Price: $2.38 AVNR Score: -25.74

Looks good but will hold off buying for now, think it will go down a little more before it starts to move up.

Recs

0
Member Avatar zandi561 (< 20) Submitted: 5/26/2010 1:26:31 PM : Outperform Start Price: $2.43 AVNR Score: -27.98

This time around it is expected that Avanir got it right with Zenvia. Lower dosage still maintains strong efficacy. FDA concern about patients overdosing has been addressed through lower dosage. QT levels are normalized after homeostasis.

Recs

0
Member Avatar jstonelake (< 20) Submitted: 3/31/2010 2:48:36 PM : Outperform Start Price: $2.40 AVNR Score: -14.12

AVNR has had many ups & downs, now they are on the upside !

Results 1 - 20 of 38 : 1 2 Next »

Featured Broker Partners


Advertisement